Latest Headlines

  1. Lantern Pharma Launches WithZeta.ai — The World's First Multi-Agentic A.I. Co-Scientist For Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events At Nasdaq MarketSite On 4/16 And At AACR 2026 From 4/17 To 4/22 4/14/2026

    Lantern Pharma Inc. (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding subscribers.

  2. Novo Nordisk And OpenAI Partner To Transform How Medicines Are Discovered And Delivered 4/14/2026

    Novo Nordisk today announced a strategic partnership with OpenAI that will place Novo Nordisk at the forefront of AI transformation in healthcare and help the company bring new and better treatment options to patients faster.

  3. Spirographic AI LLC Launches Tissue-Specific Polypharmacology Platform Demonstrating Industry-Leading Drug Target Prediction Accuracy 4/14/2026

    Spirographic AI, LLC today announced the computationally validated launch of its proprietary tissue-specific polypharmacology prediction platform, demonstrating breakthrough performance in pharmaceutical drug target identification and side effect prediction across 200 compounds and 195 biological receptors spanning 8 organ systems.

  4. Praxis Precision Medicines Announces FDA Acceptance Of New Drug Application For Ulixacaltamide HCl In Patients With Essential Tremor 4/14/2026

    Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor (ET) in adults.

  5. Vasa Therapeutics Partners With Lilly TuneLab To Power AI/ML-Driven CAMKII Inhibitor Platform 4/14/2026

    Vasa Therapeutics ("Vasa"), a clinical stage biopharmaceutical company developing transformative therapies for cardiovascular, neuromuscular, and age-related disorders, today announced an agreement with Eli Lilly and Company ("Lilly") that enables the company to utilize Lilly TuneLab, an AI-enabled drug discovery platform that provides biotech companies access to drug discovery models trained on Lilly's proprietary data.

  6. Labcorp Introduces AI-Powered Real-World Data Platform With AWS And Datavant To Accelerate Alzheimer's Research 4/14/2026

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster.

  7. Kazia Therapeutics Expands Oncology Platform With First-In-Class SETDB1 Inhibitor Drug Development Platform 4/13/2026

    Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer.

  8. New AI Tech To Speed Drug Development 4/9/2026

    School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

  9. C4 Therapeutics Expands Long-Term Partnership With Roche Through New Collaboration Agreement Focused On Discovering And Developing Degrader-Antibody Conjugates (DACs) 4/9/2026

    C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that it has entered into a new collaboration agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to advance research in the emerging degrader-antibody conjugate (DAC) modality.

  10. ANI Pharmaceuticals Announces FDA Approval And Launch Of Isosorbide Mononitrate Tablet 4/8/2026

    ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI’s Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket®.